Close Menu

Tacere Therapeutics

The rights to the intellectual property were previously licensed to Tacere Therapeutics, which is developing an shRNA-based HCV therapy with Pfizer.

Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.

For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new hepatitis C treatment, as well as a previously undisclosed eye-disease program.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

While Tacere is weighing the possible expansion of its pipeline, having met this milestone in its flagship drug-development program, the company's management has set its sights on exiting the field through the sale of the company to a bigger player.

Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

While many firms have successfully met their goals of allying with big pharmas and biotechs, others have failed to do so, despite promises of forthcoming deals.

Pages

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.